Gilead's Darusentan Posts Positive Phase III Data, Puts On Blockbuster Path
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Gilead’s darusentan, a novel drug candidate for resistant hypertension, is on its way to becoming a likely cardiovascular blockbuster after especially positive Phase III results were released April 2.